Patent classifications
C07D239/93
Methods and compositions for targeting Tregs using CCR8 inhibitors
The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
##STR00001##
Methods and Compositions for Targeting Tregs using CCR8 Inhibitors
The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
##STR00001##
Methods and Compositions for Targeting Tregs using CCR8 Inhibitors
The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
##STR00001##
2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS
The present invention relates to Na.sub.v1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X):
##STR00001##
wherein Y′, X′, B′, R.sup.1′, R.sup.2′, R.sup.3′, R.sup.5′, R.sup.6′, R.sup.7′, and z.sup.1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.
2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS
The present invention relates to Na.sub.v1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X):
##STR00001##
wherein Y′, X′, B′, R.sup.1′, R.sup.2′, R.sup.3′, R.sup.5′, R.sup.6′, R.sup.7′, and z.sup.1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.
Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
RAF kinase modulator compounds and methods of use thereof
Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
RAF kinase modulator compounds and methods of use thereof
Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
Quinazoline derivatives as TAM family kinase inhibitors
Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the modulation of the activity of, e.g., the inhibition of, one or more members of the TAM family kinases.